ADAPTOL EFFECTIVENESS IN THE THERAPY OF ANXIETY-DEPRESSIVE SYNDROME IN PATIENTS WITH SOMATIC PATHOLOGIES: A SYSTEMATIC ANALYSIS
Review
Published April 15, 2023
Keywords
emotional disorders
adaptol
anxiety
adaptol
anxiety
How to Cite
Kryzhanovsky S. M., Samushia M. A., Iosava I. K., Berestovoy M. A. ADAPTOL EFFECTIVENESS IN THE THERAPY OF ANXIETY-DEPRESSIVE SYNDROME IN PATIENTS WITH SOMATIC PATHOLOGIES: A SYSTEMATIC ANALYSIS // Kremlin Medicine Journal. 2023. VOL. № 1. С. 43-50.
Abstract
In modern society, the problem of anxiety and depression is quite relevant. Purpose. To review and to analyze summarized data on Adaptol effectiveness in the treatment of anxiety and depressive disorders in patients with various somatic pathologies. Materials and methods. This review is based on pertinent articles retrieved by a systematic search of PubMed, Cochrane, ClinicalTrials, ICTRP, GoogleScholar, eLibrary.ru, CyberLeninka by keywords and/or their combinations: "adaptol", "human", "адаптол", "clinical research". Publication period was unlimited. Data sources for analysis were selected in three stages by the developed criteria: Adaptol intake at dosage 1000 mg per day; four- and six-week course in patients with somatic pathologies; and available descriptions of outcomes (dynamics of anxiety, depressive syndrome, assessment of the quality of life). Statistical analysis was performed with specialized STATA 14.2 software. Quantitative data (most endpoints) were described using means (m) ± standard error (SE). Qualitative data were assessed by frequency in %. Differences p ≤ 0.05 were considered statistically significant. Last Observation Carried Forward procedure was used for missing data. Results. The systematic review has pooled data from 269 patients from nine trials. Assessment of the summarized data demonstrated a statistically significant reduction in anxiety after four and six weeks of therapy with Adaptol. Reactive anxiety decreased by 15.9 points and personal anxiety – by 11 points according to Spielberger-Khanin scale. Anxiety intensity decreased by 1.8 points by HADS scale. At the end of Adaptol therapy, patients had better quality of life regardless of their main nosology: indicators of physical functioning increased by three points, indicators of mental health by 4.7 points according to SF-36 scale. Conclusion. Adaptol therapy is recommended to patients with somatic problems. Adaptol therapy, being included into the basic curative course, significantly reduces level of anxiety and, as a result, improves the quality of life of patients.References
1. World Health Organization, 2022. URL: www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide.
2. Shal'nova S.A. et al. The prevalence of anxiety and depression in different regions of the Russian Federation and its association with sociodemographic factors (according to the data of the ESSE-RF study) // Terapevtichesky arkhiv (Therapeutic Archive). – 2014. – V. 86. – № 12. – P. 53–60. In Russian. doi: 10.17116/terarkh2014861253-60.
3. Neznanov N.G. et al. The prognostic role of depression as a predictor of chronic somatic diseases manifestation // Terapevtichesky arkhiv (Therapeutic Archive). – 2018. – V. 90. – № 12. – P. 122–132. In Russian. doi: 10.26442/00403660.2018.12.000019.
4. Kozhokar K.G. et al. The influence of psychosocial factors on the development of ischemic heart disease and acute coronary syndrome // Cardiovaskulyarnaya terapiya i profilaktika (Cardiovascular Therapy and Prevention). – 2016. – V. 15. – № 3. – P. 58–62. In Russian. doi: 10.15829/1728-8800-2016-3-58-62.
5. Medvedev V.E. Modern trends in research in psychosomatic medicine (according to the results of the Congress of the Association of European Psychiatrists) // Nevrologiya, neyropsikhiatriya, psikhosomatika (Neurology, neuropsychiatry, psychosomatics). – 2011. – № 2. – P. 100–102. In Russian.
6. Fishman B.B. et al. Features of the clinical picture of anxiety and depressive disorders in patients with arterial hypertension // Vestnik Sankt-Peterburgskoy gosudarstvennoy meditsinskoy akademii im. I.I. Mechnikova (Bulletin of the I.I. Mechnikov St. Petersburg State Medical Academy). – 2005. – V. 6. – № 4. – P. 156–158. In Russian.
7. Shtarik S.Yu. The relationship between increased levels of anxiety and arterial hypertension // Sibirskiy vestnik psikhiatrii i narkologii (Siberian Bulletin of Psychiatry and Narcology). – 2010. – № 2. – P. 69–73. In Russian.
8. Gafarov V.V. et al. Genetic markers for trait anxiety as one of the risk factors for cardiovascular diseases (WHOMONICA program, MONICA-Psychosocial subprogram) // Terapevticheskii arkhiv (Therapeutic Archive). – 2013. – V. 85. – № 4. – P. 47–51. In Russian.
9. Sulaymanova M.R. Anxiety and depressive syndrome in chronic somatic diseases // Vestnik Kyrgyzsko-Rossiyskogo Slavyanskogo universiteta (Bulletin of the Kyrgyz-Russian Slavic University). – 2013. – V. 13. – № 7. – P. 183–187. In Russian.
10. Gulyaevskaya N.V. et al. Analysis of the level of anxiety, depression and quality of life in individuals with an endocrinological profile // Nauchny vestnik Omskogo gosudarstvennogo meditsinskogo universiteta (Scientific Bulletin of the Omsk State Medical University). – 2021 – T. 1. – № 3. – P. 63–69. In Russian.
11. Kapustenskaya Zh.I. et al. Anxiety and depressive disorders in elderly and senile patients with chronic cerebral ischemia // Sibirsky meditsinsky zhurnal (Siberian Medical Journal) (Irkutsk). – 2009. – T. 90. – № 7. – P. 186–188. In Russian.
12. Starostina E.G. Generalized anxiety disorder and anxiety symptoms in general medical practice // Russky meditsinsky zhurnal (Russian Medical Journal). – 2004. – V. 12. – № 22. – P. 2–7. In Russian.
13. Cochrane Handbook for Systematic Reviews of Interventions. London: Cochrane; URL: https://training.cochrane.org/handbook/current.
14. Sterne J.A.C. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions // BMJ. – 2016. – V. 355. – i4919.
15. Vorob'eva O.V. et al. An open comparative observational study of the efficacy and safety of adaptol in anxiety-asthenic disorders in patients with chronic cerebral ischemia // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova (S.S. Korsakov Journal of Neurology and Psychiatry). – 2016. – Т. 116. – № 3. – P. 20–24. In Russian. doi: 10.17116/jnevro20161163120-24.
16. Barantsevich E.R. et al. Clinical-neurophysiological study of efficacy of adaptol in discirculatory encephalopathy // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova (S.S. Korsakov Journal of Neurology and Psychiatry). – 2011. – V. 111. – № 9–2. – P. 68–72. In Russian.
17. Markin S.P. et al. Treatment of anxiety disorders in postinfarction patients // KardioSomatika (CardioSomatics). – 2013. – № S1. – P. 65–66. In Russian.
18. Markin S.P. Neurotic disorders of diabetes mellitus // Nauchno-meditsinsky vestnik Tsentralnogo Chernozemya (Medical Scientific Bulletin of Central Chernozemye). – 2015. – № 59. – P. 86–89. In Russian.
19. Kozhokova L.Z. et al. The opportunities of аdaptol in treatment of patients with angina i–iii functional classes // Kardiologiya i serdechno-sosudistaya khirurgiya (Russian Journal of Cardiology and Cardiovascular Surgery). – 2014. – V. 7. – № 2. – P. 31–38. In Russian.
20. Tursunova K.B. et al. The use of adaptol in patients with chronic cervicogenic headache // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova (S.S. Korsakov Journal of Neurology and Psychiatry). – 2011. – V. 111. – № 6. – P. 68–69. In Russian.
21. Lapshina L.A. et al. Adaptol correction of psychopathological manifestations and oxidative stress in patients with myocardial infarction // Vrachebnaya praktika (Medical practice). – 2008. – V. 1. – P. 23–29. In Russian.
22. Shuteeva T.V. Methods of medical correction of neurotic and psycho-vegetative disorders in acute cerd circulation disorders // Psychology of health and disease: a clinical and psychological approach. – 2015. – P. 301–303. In Russian.
23. Lyubavskaya S.S. et al. Complex therapy of chronic pancreatitis complicated by anxio-depressive disorders in railroad workers // Research Results in Pharmacology. – 2016. – V. 2. – № 4. – P. 73–86. doi: 10.18413/2500-235X-2016-2-4-73-86.
2. Shal'nova S.A. et al. The prevalence of anxiety and depression in different regions of the Russian Federation and its association with sociodemographic factors (according to the data of the ESSE-RF study) // Terapevtichesky arkhiv (Therapeutic Archive). – 2014. – V. 86. – № 12. – P. 53–60. In Russian. doi: 10.17116/terarkh2014861253-60.
3. Neznanov N.G. et al. The prognostic role of depression as a predictor of chronic somatic diseases manifestation // Terapevtichesky arkhiv (Therapeutic Archive). – 2018. – V. 90. – № 12. – P. 122–132. In Russian. doi: 10.26442/00403660.2018.12.000019.
4. Kozhokar K.G. et al. The influence of psychosocial factors on the development of ischemic heart disease and acute coronary syndrome // Cardiovaskulyarnaya terapiya i profilaktika (Cardiovascular Therapy and Prevention). – 2016. – V. 15. – № 3. – P. 58–62. In Russian. doi: 10.15829/1728-8800-2016-3-58-62.
5. Medvedev V.E. Modern trends in research in psychosomatic medicine (according to the results of the Congress of the Association of European Psychiatrists) // Nevrologiya, neyropsikhiatriya, psikhosomatika (Neurology, neuropsychiatry, psychosomatics). – 2011. – № 2. – P. 100–102. In Russian.
6. Fishman B.B. et al. Features of the clinical picture of anxiety and depressive disorders in patients with arterial hypertension // Vestnik Sankt-Peterburgskoy gosudarstvennoy meditsinskoy akademii im. I.I. Mechnikova (Bulletin of the I.I. Mechnikov St. Petersburg State Medical Academy). – 2005. – V. 6. – № 4. – P. 156–158. In Russian.
7. Shtarik S.Yu. The relationship between increased levels of anxiety and arterial hypertension // Sibirskiy vestnik psikhiatrii i narkologii (Siberian Bulletin of Psychiatry and Narcology). – 2010. – № 2. – P. 69–73. In Russian.
8. Gafarov V.V. et al. Genetic markers for trait anxiety as one of the risk factors for cardiovascular diseases (WHOMONICA program, MONICA-Psychosocial subprogram) // Terapevticheskii arkhiv (Therapeutic Archive). – 2013. – V. 85. – № 4. – P. 47–51. In Russian.
9. Sulaymanova M.R. Anxiety and depressive syndrome in chronic somatic diseases // Vestnik Kyrgyzsko-Rossiyskogo Slavyanskogo universiteta (Bulletin of the Kyrgyz-Russian Slavic University). – 2013. – V. 13. – № 7. – P. 183–187. In Russian.
10. Gulyaevskaya N.V. et al. Analysis of the level of anxiety, depression and quality of life in individuals with an endocrinological profile // Nauchny vestnik Omskogo gosudarstvennogo meditsinskogo universiteta (Scientific Bulletin of the Omsk State Medical University). – 2021 – T. 1. – № 3. – P. 63–69. In Russian.
11. Kapustenskaya Zh.I. et al. Anxiety and depressive disorders in elderly and senile patients with chronic cerebral ischemia // Sibirsky meditsinsky zhurnal (Siberian Medical Journal) (Irkutsk). – 2009. – T. 90. – № 7. – P. 186–188. In Russian.
12. Starostina E.G. Generalized anxiety disorder and anxiety symptoms in general medical practice // Russky meditsinsky zhurnal (Russian Medical Journal). – 2004. – V. 12. – № 22. – P. 2–7. In Russian.
13. Cochrane Handbook for Systematic Reviews of Interventions. London: Cochrane; URL: https://training.cochrane.org/handbook/current.
14. Sterne J.A.C. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions // BMJ. – 2016. – V. 355. – i4919.
15. Vorob'eva O.V. et al. An open comparative observational study of the efficacy and safety of adaptol in anxiety-asthenic disorders in patients with chronic cerebral ischemia // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova (S.S. Korsakov Journal of Neurology and Psychiatry). – 2016. – Т. 116. – № 3. – P. 20–24. In Russian. doi: 10.17116/jnevro20161163120-24.
16. Barantsevich E.R. et al. Clinical-neurophysiological study of efficacy of adaptol in discirculatory encephalopathy // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova (S.S. Korsakov Journal of Neurology and Psychiatry). – 2011. – V. 111. – № 9–2. – P. 68–72. In Russian.
17. Markin S.P. et al. Treatment of anxiety disorders in postinfarction patients // KardioSomatika (CardioSomatics). – 2013. – № S1. – P. 65–66. In Russian.
18. Markin S.P. Neurotic disorders of diabetes mellitus // Nauchno-meditsinsky vestnik Tsentralnogo Chernozemya (Medical Scientific Bulletin of Central Chernozemye). – 2015. – № 59. – P. 86–89. In Russian.
19. Kozhokova L.Z. et al. The opportunities of аdaptol in treatment of patients with angina i–iii functional classes // Kardiologiya i serdechno-sosudistaya khirurgiya (Russian Journal of Cardiology and Cardiovascular Surgery). – 2014. – V. 7. – № 2. – P. 31–38. In Russian.
20. Tursunova K.B. et al. The use of adaptol in patients with chronic cervicogenic headache // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova (S.S. Korsakov Journal of Neurology and Psychiatry). – 2011. – V. 111. – № 6. – P. 68–69. In Russian.
21. Lapshina L.A. et al. Adaptol correction of psychopathological manifestations and oxidative stress in patients with myocardial infarction // Vrachebnaya praktika (Medical practice). – 2008. – V. 1. – P. 23–29. In Russian.
22. Shuteeva T.V. Methods of medical correction of neurotic and psycho-vegetative disorders in acute cerd circulation disorders // Psychology of health and disease: a clinical and psychological approach. – 2015. – P. 301–303. In Russian.
23. Lyubavskaya S.S. et al. Complex therapy of chronic pancreatitis complicated by anxio-depressive disorders in railroad workers // Research Results in Pharmacology. – 2016. – V. 2. – № 4. – P. 73–86. doi: 10.18413/2500-235X-2016-2-4-73-86.